-

Shareholder Alert: Robbins LLP Announces STAAR Surgical Company (STAA) Sued for Misleading Shareholders

SAN DIEGO & LAKE FOREST, Calif.--(BUSINESS WIRE)--Shareholder rights law firm Robbins LLP announces that a purchaser of STAAR Surgical Company (NASDAQ: STAA) filed a class action complaint against the Company for alleged violations of the Securities Exchange Act of 1934 between February 26, 2020 and August 10, 2020. STAAR Surgical designs, develops, manufactures, markets, and sells implantable lenses for the eye and delivery systems to deliver the lenses into the eye.

If you suffered a loss due to STAAR Surgical's misconduct, click here.

STAAR Surgical Company (STAA) Accused of Misleading Shareholders

According to the complaint, STAAR Surgical reported positive financial results for its fourth quarter and fiscal year ended January 3, 2020. STAAR Surgical reiterated its positive financial results in its COVID-19 business update and first quarter 2020 earnings report, each time, noting the Company's strong relationship with its distributor in China. However, on August 5, 2020, STAAR Surgical reported decreased net sales and a net loss of $0.03 per share for second quarter 2020. On this news, the Company's share price fell approximately 10%, to close at $55.86 on August 6, 2020. Then, on August 2020, J Capital Research released a scathing report asserting that the Company may have "overstated sales in China by at least one-third, or $21.6 million" meaning "all of the company's $14 million in 2019 profit is fake." The report noted, "without the fraud that we believe pervades the China business, STAAR is losing money." On this news, the Company's share price fell approximately 6.2%, to close at $48.25 per share on August 11, 2020. The stock continues to decline.

If you purchased STAAR Surgical Company (STAA) shares between February 26, 2020, and August 10, 2020, you have until October 19, 2020, to ask the court to appoint you lead plaintiff for the class.

Contact us to learn more:
Lauren Levi
(800) 350-6003
llevi@robbinsllp.com
Shareholder Information Form

Robbins LLP is a nationally recognized leader in shareholder rights law. To be notified if a class action against STAAR Surgical settles or to receive free alerts about companies engaged in wrongdoing, sign up for Stock Watch today.

Attorney Advertising. Past results do not guarantee a similar outcome.

Contacts

Lauren Levi
Robbins LLP
5040 Shoreham Place
San Diego, CA 92122
llevi@robbinsllp.com
(800) 350-6003

Robbins LLP

NASDAQ:STAA

Release Versions
$Cashtags

Contacts

Lauren Levi
Robbins LLP
5040 Shoreham Place
San Diego, CA 92122
llevi@robbinsllp.com
(800) 350-6003

More News From Robbins LLP

Robbins LLP Urges GOSS Stockholders to Contact the Firm for Information About the Class Action Against Gossamer Bio, Inc.

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Gossamer Bio, Inc. (NASDAQ: GOSS) securities between June 16, 2025 and February 20, 2026. Gossamer is a clinical stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary hypertension (PH) associated with interstitial lung disease.For more information, submit a form, email att...

Robbins LLP Urges IBRX Stockholders to Contact the Firm for Information About the Class Action Against ImmunityBio, Inc.

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired ImmunityBio, Inc. (NASDAQ: IBRX) securities between January 19, 2026 and March 25, 2026. ImmunityBio is a biotechnology company and ANKTIVA is the Company's lead biologic product. For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. What is the class period? January 19, 2026 – March 25, 202...

Robbins LLP Reminds ALDX Investors of the Pending Class Action Lawsuit; Harmed Investors Should Contact the Firm for Information About Leading the Case Against Aldeyra Therapeutics, Inc.

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) securities between November 3, 2023 and March 16, 2026. Defendant Aldeyra describes itself as a “biotechnology company devoted to discovering innovative therapies designed to treat immune-mediated diseases.” Pertinent to this action is reproxalap, which is a novel reactive aldehyde species (RASP) inhib...
Back to Newsroom